|
GenScript corporation
cpass sars-cov-2 surrogate virus neutralisation test (svnt) Cpass Sars Cov 2 Surrogate Virus Neutralisation Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/med_rxiv__2023__03__30__23287981-61-16-23?v=GenScript+corporation Average 90 stars, based on 1 article reviews
cpass sars-cov-2 surrogate virus neutralisation test (svnt) - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
surrogate virus neutralization test (svnt) cpass assay Surrogate Virus Neutralization Test (Svnt) Cpass Assay, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pm35707164-49-1-37?v=GenScript+corporation Average 90 stars, based on 1 article reviews
surrogate virus neutralization test (svnt) cpass assay - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
cpass surrogate virus neutralization test (svnt) ![]() Cpass Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc09130843-123-27-33?v=GenScript+corporation Average 90 stars, based on 1 article reviews
cpass surrogate virus neutralization test (svnt) - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
cpass svnt ![]() Cpass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc09643483-172-2-1?v=GenScript+corporation Average 90 stars, based on 1 article reviews
cpass svnt - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
svnt genscript c-pass biotech ![]() Svnt Genscript C Pass Biotech, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pm37766101-59-34-35?v=GenScript+corporation Average 90 stars, based on 1 article reviews
svnt genscript c-pass biotech - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
cpass svnt kit ![]() Cpass Svnt Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc09046723-178-3-2?v=GenScript+corporation Average 90 stars, based on 1 article reviews
cpass svnt kit - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
genscript cpass svnt ![]() Genscript Cpass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pm36462465-119-26-25?v=GenScript+corporation Average 90 stars, based on 1 article reviews
genscript cpass svnt - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
c-pass svnts ![]() C Pass Svnts, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pm40142493-206-1-1?v=GenScript+corporation Average 90 stars, based on 1 article reviews
c-pass svnts - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
c-pass svnt ![]() C Pass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc08183028-89-11-15?v=GenScript+corporation Average 90 stars, based on 1 article reviews
c-pass svnt - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
elisa-based tests ![]() Elisa Based Tests, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc10573711-110-8-12?v=GenScript+corporation Average 90 stars, based on 1 article reviews
elisa-based tests - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
cpass® assay ![]() Cpass® Assay, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pm37078220-133-5-4?v=GenScript+corporation Average 90 stars, based on 1 article reviews
cpass® assay - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
EUROIMMUN
sars-cov-2-neutralisa ![]() Sars Cov 2 Neutralisa, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/surrogate+viral+neutralization+test+c-pass+genscript+svnt/pmc09603218__spectrum__02129___22___s0001-59-42-79?v=EUROIMMUN Average 90 stars, based on 1 article reviews
sars-cov-2-neutralisa - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Frontiers in Immunology
Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
doi: 10.3389/fimmu.2022.833085
Figure Lengend Snippet: Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the cPass™ ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).
Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the
Techniques: Binding Assay, Activity Assay, Vaccines, Inhibition, Enzyme-linked Immunosorbent Assay
Journal: Frontiers in Immunology
Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
doi: 10.3389/fimmu.2022.833085
Figure Lengend Snippet: Neutralizing activity evaluated by cPass™ ELISA-based SARS-CoV-2 Neutralization Antibody Detection Kit in 70 sera from differently vaccinated individuals. Serum samples were considered positive when ≥30% inhibition was measured, as shown by the red line in the graph. (A) Percentage inhibition of receptor-binding domain–angiotensin-converting enzyme 2 (RBD-ACE2) binding within different vaccination groups (see also
Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the
Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Neutralization, Inhibition, Binding Assay, Comparison, Vaccines
Journal: Frontiers in Immunology
Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
doi: 10.3389/fimmu.2022.833085
Figure Lengend Snippet: Mean neutralizing activity measured by the cPass™ ELISA-based assay in sera from 70 individuals who received different vaccines.
Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the
Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Vaccines
Journal: Scientific Reports
Article Title: Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies
doi: 10.1038/s41598-022-21317-x
Figure Lengend Snippet: Analytical performance of the evaluated sVNT assays using the pre-defined cutoff values and the newly calculated cutoff values determined using Youden's index.
Article Snippet: Further,
Techniques: Infection
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.
Article Snippet: For the
Techniques: Infection
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.
Article Snippet: For the
Techniques: Activity Assay
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.
Article Snippet: For the
Techniques: Activity Assay
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.
Article Snippet: For the
Techniques:
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Antibody titers by timeline.
Article Snippet: For the
Techniques:
Journal: Frontiers in Cellular and Infection Microbiology
Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
doi: 10.3389/fcimb.2022.822599
Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.
Article Snippet: For the
Techniques:
Journal: medRxiv
Article Title: Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination
doi: 10.1101/2021.06.02.21257975
Figure Lengend Snippet: Panel A shows the mean time of sample collection following natural infection (n=25) or after the first vaccine dose (n=20). In panel B and C, results from the total anti-Spike protein and the IgG titer measured by Enzyme-linked immunosorbent assay and expressed as OD or titers respectively are presented. The threshold for the total antibodies was 0.312 and the threshold for IgG titers was 1:100. All participants, except one, with previous exposure to SARS-CoV-2 showed detectable antibodies and measurable titers at baseline. Because the threshold 1:100 of our titration assay, the IgG titers at baseline in the unexposed subjects—which had no detectable S-specific antibodies—were set arbitrarily to 50. Panel D shows the blocking activity of serum antibodies expressed as percentage of neutralization by using a surrogate viral neutralization test (sVNT). The cutoff for this assay was 30%. As is shown, only one sample in the pre-exposed group contained antibodies below the threshold reported as more than 30% of neutralization. Also, while the distribution of antibodies and titers covers the full Y axis, values in both panel B and C, and in panel D same samples are grouped on the top values area. Two-way ANOVA multiple comparisons or unpaired T test analysis was used to test for increases or decreases among samples. P<0.05 was considered significant. Twenty-five participants (Natural infected) out of the 59 with the first sample collected between 12 and 39 days after the confirmed infection with SARS-CoV-2 were selected for comparison with the 21 unexposed-vaccinated subgroup (Healthy-vaccinated).
Article Snippet: To determine the neutralizing activity of antibodies we used a surrogate
Techniques: Infection, Enzyme-linked Immunosorbent Assay, Titration, Blocking Assay, Activity Assay, Neutralization, Comparison
Journal: medRxiv
Article Title: Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination
doi: 10.1101/2021.06.02.21257975
Figure Lengend Snippet: Samples are described as 1st or 2nd samples after 1 st or 2 nd vaccine dose (1S-P1st-vd, 1S-P2nd-vd or 2S-P2nd-vd) and the mean time of samples collection is shown. Panels A and B show the total antibody and IgG titers, respectively, after full vaccination with two vaccine doses. Antibody levels and titers significantly decay in both groups in a second sample collected after the second vaccine (average of 60.3 and 100.5 days after the first vaccine dose for the unexposed and pre-exposed groups respectively). Despite the difference in sampling time between the two groups, there were no significant differences in the levels of antibodies or titers between groups in the 2S-P2nd-vd. Panel C shows antibody blocking capabilities measured by a surrogate viral neutralization assay (sVNT). Highly relevant is the finding that the blocking baseline activity of the pre-exposed individuals is significantly higher than the basely blocking activity induced by the first vaccine dose in unexposed individuals. In addition, two vaccine doses were necessary in the unexposed cohort to induce same percentage of neutralization achieved by just the first dose in the pre-exposed group. The magnitude of neutralization remained at similar levels until the last time point evaluated in both groups, confirming that the surrogate neutralization test is more suitable to determine the efficacy of the humoral immune response to the vaccine. The threshold for the total antibodies was 0.312. The threshold for IgG titers was 1:100 and for the blocking activity was 30%. Statistical significance was determined by two-way ANOVA multiple comparisons to test for increase or decrease among samples. p<0.05 was considered significant. The black arrows indicate the moment of vaccine administration related to the timing of sample collection. Healthy-vaccinated (n=21) Pre-exposed vaccinated (n=10).
Article Snippet: To determine the neutralizing activity of antibodies we used a surrogate
Techniques: Sampling, Blocking Assay, Neutralization, Activity Assay